Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
mZqKMVABBgtwrTBL
Listen
